Navigation Links
Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
Date:10/12/2007

V.P. Business Development, Functional Food, will take over all nutraceutical business activities as V.P. Nutraceutical, since Neptune did not renew the contract of its V.P. Sales and Marketing, Donald Allard.

Neptune is also pleased to announce that Toni Rinow, Ph.D., MBA, has joined the team. She will be responsible for Investors Relations and Corporate Development. "Dr. Rinow, former Senior V.P., Fonds de Solidarite, will be an important asset to the company because of her experience in the capital markets, especially with life science companies. We believe that, because of her knowledge, reputation and networking contacts, Dr. Rinow will be able to bring market value recognition to Neptune," stated Mr. Henri Harland, President and Chief Executive Officer.

Neptune would also like to inform its shareholders that since its shares are listed on NASDAQ, it will be filing its quarterly and annual results respectively, not more than 45 days and 90 days after the applicable period as compared to not more than 60 and 120 days previously.

About Neptune Technologies & Bioressources, Inc.

Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

NASDAQ and TSX
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- An analysis by Replikins, Ltd. of Pubmed data ... virus strains has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
(Date:8/26/2014)... Israel , August 26, 2014 ... 3DM, supports NHS hospitals with surgery validation using its Stratasys ... - Performing surgery on 3D printed models prior to ... and provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... Presented at 21st North American Cystic Fibrosis ... Findings in Adult population -, SOUTH PLAINFIELD, ... Inc.,(PTC), a biopharmaceutical company focused on the discovery, ... today announced encouraging data,from a Phase 2 clinical ...
... RIDGE, N.J., Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin ... acquiring, developing and,commercializing targeted cancer therapeutics, announced today ... Thursday, October 11, 2007 at 2:00 p.m.,Pacific Time ... Room in San Francisco.,Daniel Greenleaf, VioQuest,s president and ...
... SOMERSET, N.J., Oct. 5 Alfacell Corporation,(Nasdaq: ACEL ... call and,Webcast at 11 a.m. EDT on Monday, Oct. ... executive officer, and Lawrence A. Kenyon,executive vice president, chief ... Alfacell,s financial performance for the fiscal,fourth quarter and year ...
Cached Biology Technology:PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 2PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 3PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 4PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis 5VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast 2
(Date:8/27/2014)... Africa is entering what is described by the Volunteer ... The Eastern Cape provincial government warned residents in ... strong winds and veld fires. A high veld ... and along the coast in the Great Kei and ... regions, and during thunderstorms. The thunderstorms bring lightning ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
(Date:8/27/2014)... Thousands of fishing traps are lost or abandoned each ... as derelict traps, which continue to catch fish, crabs, ... in losses to habitat, fisheries, and the watermen who ... to a newly published NOAA study. , The report, ... the first of its kind to examine the derelict ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... A person,s ability to battle viruses at the cellular ... prions misfold and cluster native proteins to cause disease, ... marks the first discovery of so-called "good" prion-like proteins ... proteins involved in innate immunity: the way the body ...
... University professor is helping students improve their confidence ... learning. Candice Shoemaker, professor of horticulture, has ... and self-efficacy. Self-efficacy involves student confidence in understanding ... learning and achievement. Shoemaker,s published research appeared in ...
... be a leading cause of the decline of coral reefs ... Georgia have found that extreme low temperatures affect certain corals ... potentially catastrophic consequences for coral ecosystems. Their findings appear in ... Biology . Lead author Dustin Kemp, a postdoctoral associate ...
Cached Biology News:'Good' prion-like proteins boost immune response, UT Southwestern scientists report 2Finding their way: Study shows connection between academic direction and student learning 2Finding their way: Study shows connection between academic direction and student learning 3Study: Severe low temperatures devastate coral reefs in Florida Keys 2Study: Severe low temperatures devastate coral reefs in Florida Keys 3
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
...
... is a 96-well ELISA-compatible plate (containing 12 x ... Monoclonal Antibody is immobilized by a method that ... the tail fiber protein of the T7 bacteriophage. ... 10 9 phage per well and low ...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: